Pre-Clinical Study Evaluating Novel Protein Phosphatase 2A Activators as Therapeutics for Neuroblastoma

SIMPLE SUMMARY: Despite significant advancements in neuroblastoma therapy, over half of the children with high-risk neuroblastoma will suffer disease relapse. Protein phosphatase 2A (PP2A) is a tumor suppressor that is decreased in neuroblastoma. Previous studies with FTY720, an immunomodulatory age...

Descripción completa

Detalles Bibliográficos
Autores principales: Bownes, Laura V., Marayati, Raoud, Quinn, Colin H., Beierle, Andee M., Hutchins, Sara C., Julson, Janet R., Erwin, Michael H., Stewart, Jerry E., Mroczek-Musulman, Elizabeth, Ohlmeyer, Michael, Aye, Jamie M., Yoon, Karina J., Beierle, Elizabeth A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9026148/
https://www.ncbi.nlm.nih.gov/pubmed/35454859
http://dx.doi.org/10.3390/cancers14081952

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9026148/
https://www.ncbi.nlm.nih.gov/pubmed/35454859
http://dx.doi.org/10.3390/cancers14081952

Ejemplares similares